Lung cancer remains one of the leading causes of cancer deaths around the world. Among the different types of lung cancer, non‑small cell lung cancer (NSCLC) is the most common. It accounts for about 85% of all lung cancer cases.
Although treatments for this disease have improved over the past decade, many patients still face limited options, especially when their tumors do not respond to modern immunotherapy drugs.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has uncovered a promising strategy that may help treat certain forms of lung cancer that resist current therapies.
The research was published in the journal Science Translational Medicine and focuses on a new way of targeting how cancer cells survive and grow.
The study specifically examined two major subtypes of NSCLC: squamous cell carcinoma and adenocarcinoma. These cancers can sometimes be treated with immunotherapy, which works by helping the immune system recognize and attack cancer cells.
However, not all patients respond well to these treatments. When immunotherapy fails, doctors often have very few effective options left.
The research team wanted to understand why some lung tumors continue to survive despite treatments that should weaken them. Their investigation focused on structures inside cells called lysosomes.
Lysosomes are small compartments that act like recycling centers inside the cell. They break down waste materials and help maintain a stable supply of nutrients that cells need to survive.
Cancer cells depend heavily on lysosomes because tumors grow quickly and require large amounts of energy and building materials. For this reason, scientists have been studying drugs that block lysosome activity. One such drug is chloroquine, a medication that has long been used to treat malaria.
Researchers have tried combining chloroquine with chemotherapy, radiation, and other cancer treatments in clinical trials. Unfortunately, the results have only been moderately successful.
The new study aimed to find out why blocking lysosomes alone has not been very effective against tumors. The researchers discovered that cancer cells have a backup survival strategy.
When lysosomes are blocked, tumors activate a protein known as SREBP‑1. This protein helps cancer cells take in more glucose, which is a type of sugar used for energy. By increasing glucose uptake, tumor cells can continue to survive and grow even when lysosomes are not functioning normally.
This discovery revealed that cancer cells are highly adaptable. When one survival pathway is blocked, they activate another pathway to keep growing. The researchers found that glucose metabolism and fat metabolism work together in a type of reinforcing cycle that helps tumors resist treatment.
In laboratory experiments using cancer cell lines and animal models, the team tested what would happen if both survival pathways were targeted at the same time. They found that blocking glucose transport while also inhibiting lysosomes caused serious damage to tumor cells.
This combination created stress inside the cells, damaged their mitochondria, and eventually caused cancer cells to die.
Dr. Deliang Guo, the senior author of the study and founding director of the Center for Cancer Metabolism at the OSUCCC–James, explained that this research reveals a previously unknown way that tumors protect themselves. According to Guo, the findings suggest that attacking several metabolic pathways at once may be far more effective than focusing on just one.
The study’s first author, Dr. Yaogang Zhong, said that the work provides a clear strategy for developing combination treatments. By targeting lysosome function together with the glucose‑lipid metabolic feedback loop, doctors may be able to weaken tumors much more effectively.
Another encouraging aspect of the research is that several of the drugs involved are already approved for medical use. Chloroquine, the lysosome‑blocking drug used in the experiments, has been used safely in humans for decades.
Simvastatin, a cholesterol‑lowering medication, may also help disrupt tumor metabolism. In addition, a drug called TVB‑2640, which blocks fatty acid production, has already entered advanced clinical trials for cancer treatment.
Because these medications are already known to be relatively safe, researchers believe that testing new combinations of them in clinical trials could happen faster than developing an entirely new drug from the beginning.
The findings are particularly important for patients whose lung cancers do not have specific genetic mutations that can be targeted with existing therapies. These patients often have very limited treatment options once standard therapies fail. The combination strategy suggested by this research could provide a new path forward.
When reviewing the study as a whole, it highlights an important shift in how scientists think about cancer treatment. Instead of attacking only one weak point in a tumor, researchers are increasingly looking at the complex networks that allow cancer cells to survive.
Tumors are extremely flexible and can change their metabolism to escape treatment. By targeting several survival mechanisms at the same time, doctors may have a better chance of stopping cancer growth.
However, it is also important to recognize that this research is still at the preclinical stage. The experiments were conducted using cell cultures and animal models, which means more studies are needed before the approach can be confirmed as safe and effective in human patients.
Clinical trials will be necessary to determine whether the drug combinations work as well in people as they do in laboratory experiments.
Even with these limitations, the study provides valuable insight into how lung tumors resist treatment and offers a promising direction for future therapies. If the strategy proves successful in human trials, it could lead to more effective treatments not only for lung cancer but also for other cancers that depend heavily on glucose and fat metabolism.
The research therefore represents an important step toward developing smarter and more targeted cancer therapies that attack the disease on multiple fronts.
If you care about lung, please read studies about a review of COPD-friendly foods for lung health, and can Vitamin C and E help fight lung cancer.
For more health information, please see recent studies about how diet influences lung health, and these vegetables could benefit your lung health.
Copyright © 2026 Knowridge Science Report. All rights reserved.
